Tack Optimized Drug Coated Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries (TOBA III)

Philips

Status

Completed

Conditions

Peripheral Arterial Disease

Treatments

Device: Tack Endovascular System

Study type

Interventional

Funder types

Industry

Identifiers

NCT02802306

CA 0135

Details and patient eligibility

About

This is an Outside the United States, post-CE Mark, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System. This study will evaluate subjects with PAD who receive PTA (with a drug-coated balloon (DCB)) in the SFA and in popliteal arteries, ranging in diameter from 2.5mm to 6.0mm and lesion lengths of ≥20mm and ≤150mm, and have a resulting dissection(s) type(s) A through F. TOBA III will also evaluate the safety and efficacy of the device when used to treat a sub-group presenting with longer lesions of >150mm and ≤250mm.

Enrollment

201 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject must meet all of the following inclusion criteria to be eligible for enrollment:
1. Male or non-pregnant Female ≥ 18 years of age at the time of consent
2. Female subjects of childbearing potential must have a negative pregnancy test prior to treatment and must use some form of contraception through the duration of the study
3. Target limb requires no additional treatment aside from the target lesion and the iliac artery(ies) during the index procedure
4. Subject or has been informed of and understands the nature of the study and provides signed informed consent to participate in the study. If the subject possesses the ability to understand and provide informed consent but due to physical inability, the subject cannot sign the ICF, an impartial witness may sign on behalf of the subject
5. Willing to comply with all required follow-up visits
6. Rutherford Classification 2, 3 or 4
7. Estimated life expectancy >1 year
8. Eligible for standard surgical repair, if necessary
9. Subject is ambulatory (assistive devices such as a cane or walker is acceptable

Exclusion criteria

Subject must NOT meet any of the following exclusion criteria to be eligible for enrollment:
1. Rutherford Classification 0, 1, 5 or 6
2. Is pregnant or refuses to use contraception through the duration of the study
3. Previous infrainguinal bypass graft in the target limb
4. Planned amputation on the target limb
5. Systemic infection or infection within the target limb and/or immunocompromised
6. Endovascular or surgical procedure (not including diagnostic procedures) on the target limb within 30 days prior to or within 30 days after the index procedure
7. Endovascular or surgical procedure (not including diagnostic procedures) on the non-target limb within 14 days prior to the index procedure or planned procedure within 30 days after the index procedure
8. Prior coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) procedure within 30 days prior to the index procedure or planned CABG/PCI within 30 days after the index procedure
9. Any other previous or planned surgical or endovascular procedure (not including diagnostic procedures) within 14 days prior to or 30 days post index procedure
10. Planned atherectomy, cryoplasty, stenting or any other treatment (with the exception of a crossing device) of the target lesion other than PTA during the index procedure
11. Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80,000/microliter or greater than 500,000/microliter
12. Known hypersensitivity or allergy to antiplatelet or anticoagulant therapy
13. Myocardial infarction within 30 days prior to enrollment
14. History of stroke within 90 days prior to enrollment
15. Serum creatinine of >2.5 mg/dL
16. Requires treatment of tibial or outflow vessels at the index procedure, which include the P2 and P3 segments of the popliteal artery and the tibioperoneal vessels
17. Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol)
18. Participating in another ongoing investigational clinical trial that has not completed its primary endpoint
19. Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments
20. Known hypersensitivity or allergy to contrast agents that cannot be medically managed
21. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved